Biomarin Pharmaceutical Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 07:30PM GMT
David Neil Lebowitz - Citigroup Inc., Research Division - Research Analyst

Hello. Thank you all for coming again to the 18th Annual Citi Biopharma Conference. Happy to have on stage with me from BioMarin, certainly been an exciting last few years, biggest commercial launch in history with Voxzogo the upcoming or ongoing launch as of just recently, launch of Roctavian for hemophilia A and of course, a large portfolio of ultra-rare diseases.

Questions and Answers:

David Neil Lebowitz - Citigroup Inc., Research Division - Research Analyst

Could you start by walking us through BioMarin, its history and really these transformative recent years?

Brian R. Mueller - BioMarin Pharmaceutical Inc. - CFO & Executive VP

Great. Thanks. Thanks, David. Thanks for having us. Thanks for participating, everyone. And yes, BioMarin has been on a steady growth journey throughout our 25-year history. We grew up around mostly ultra-orphan therapies. These are ultra-rare metabolic disorders, very small patient populations, very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot